SCHEMBL16797266

SCHEMBL16797266

CC(C)(C)OC(=O)N1CCCC(CNc2ncc(Cl)c(-c3ccc(C#N)cc3)n2)C1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.55
▸ IRAK1 P51617 1/20 0.46
▸ ACKR3 P25106 1/20 0.44
▸ MERTK Q12866 1/20 0.44
▸ MAPK1 P28482 3/20 0.44
▸ EGLN2 Q96KS0 1/20 0.44
▸ GPR119 Q8TDV5 2/20 0.43
▸ CHEK2 O96017 1/20 0.43
▸ CCNT1 O60563 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ BCHE P06276 2/20 0.40
▸ HTR6 P50406 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16808849 0.95 KDM1A (0.56) KDM1AIRAK1MERTKMAPK1EGLN2
SCHEMBL24659688 0.95 KDM1A (0.56) KDM1AIRAK1MERTKMAPK1EGLN2
SCHEMBL16797291 0.90 KDM1A (0.58) KDM1AEGLN2GPR119
SCHEMBL16797316 0.86 MAPK1 (0.50) KDM1AMAPK1EGLN2GPR119
SCHEMBL30034326 0.86 MAPK1 (0.50) KDM1AMAPK1EGLN2GPR119
SCHEMBL17686615 0.85 KDM1A (0.48) KDM1AMAPK1EGLN2GPR119
SCHEMBL30034274 0.83 IDO1 (0.45) KDM1AIRAK1EGLN2GPR119CCNT1
SCHEMBL17559060 0.83 KDM1A (0.62) KDM1AMERTKMAPK1EGLN2
SCHEMBL16797362 0.82 KDM1A (0.63) KDM1AMAPK1
SCHEMBL16808869 0.81 GPR119 (0.46) EGLN2GPR119CHEK2CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257591-A2 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2023-10-11 — — EP disclosed
EP-3080100-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-30 — — EP disclosed
US-10864202-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-12-15 — — US disclosed
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-09 — — US disclosed
US-10543198-B2 Inhibitor of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-01-28 — — US disclosed
US-10385051-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2019-08-20 — — US disclosed
US-20190055242-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2019-02-21 — — US disclosed
US-10131664-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-11-20 — — US disclosed
US-20180179204-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2018-06-28 — — US disclosed
US-9944636-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2018-04-17 — — US disclosed
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2018-02-01 — — US disclosed
US-9822119-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-21 — — US disclosed
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. 2016-10-20 — — US disclosed
EP-3080100-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Celgene Quanticel Research, Inc. (US) 2016-10-19 — — EP disclosed
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 — — US disclosed
WO-2015089192-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. (US) 2015-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179204-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-10864202-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-10131664-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-20190055242-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885
US-10543198-B2 Inhibitor of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1152/4885ACKR3 4666/4885
US-10385051-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A KDM1A 2/4885IRAK1 1213/4885ACKR3 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback